SALEM, N.H. -- (BUSINESS WIRE) -- PixarBio Corporation today announced that it has signed a five year lease agreement for their new corporate headquarters and research center to be located at 200 Boston Avenue, Medford, MA. At just under 8,000 sq. ft., the facility will house state-of-the-art Chemical, Bio, and Tissue labs. The company will also move its corporate headquarters to the Medford, MA facility from Salem, NH. Located in close proximity to its innovation roots at Harvard and MIT PixarBio Corp will have capacity to quickly expand beyond biomaterials needed for Parkinson’s disease to include biomaterials for Epilepsy.
“We are building a home for our world renowned and award winning team of researchers to drive innovation and accelerate the development of new treatment options for Parkinson’s disease. We’re confident that our optimized R&D model will generate key intellectual property permitting PixarBio to lead the development of next generation biomaterials for the treatment of Parkinson’s disease as well as a range of chronic neurological conditions,” says CTO Randy Holmes-Farley, PhD.
Frank Reynolds, PixarBio’s CEO adds, “We’ll move to Medford, MA in early 2014 and get to work on achieving our objective of rapidly bringing a new Parkinson’s treatment to market. Along the way we’ll explore M&A in the biomaterials space while focusing on expanding our platform.”
PixarBio Corporation is dedicated to developing new therapeutic options for Parkinson’s disease and Epilepsy. Cofounded by Robert S. Langer from MIT’s Langer Lab, Frank Reynolds, Katrin Holzhaus, and Randy Holmes-Farley the company is developing novel smart materials to achieve sustained release of dopamine, or dopamine agonists. Research is focused on a platform for chronic neurological applications. For more information, please visit www.pixarbio.com.